Orbital Gallium-67 Scintigraphy in Graves' Ophthalmopathy: A Disease Activity Parameter that Predicts the Therapeutic Response to Immunosuppressive Treatment

Thyroid ◽  
2005 ◽  
Vol 15 (4) ◽  
pp. 358-363 ◽  
Author(s):  
Onur Konuk ◽  
Tamer Atasever ◽  
Mehmet Unal ◽  
Goksun Ayvaz ◽  
Ilhan Yetkin ◽  
...  
Keyword(s):  
Disease Activity ◽  
Therapeutic Response ◽  
Immunosuppressive Treatment ◽  
Activity Parameter ◽  
Disease Activity Parameter ◽  
Graves Ophthalmopathy ◽  
Gallium 67

Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy

1999 ◽  
Vol 50 (3) ◽  
pp. 373-379 ◽  
Author(s):  
M. N. Gerding ◽  
F. M. van der Zant ◽  
E. A. van Royen ◽  
L. Koornneef ◽  
E. P. Krenning ◽  
...  
Keyword(s):  
Disease Activity ◽  
Activity Parameter ◽  
Disease Activity Parameter ◽  
Graves Ophthalmopathy ◽  
Octreotide Scintigraphy

A New Ultrasonographic Method to Detect Disease Activity and Predict Response to immunosuppressive Treatment in Graves Ophthalmopathy

Ophthalmology ◽  
1993 ◽  
Vol 100 (4) ◽  
pp. 556-561 ◽  
Author(s):  
Mark F. Prummel ◽  
Maria S.A. Suttorp-Schulten ◽  
Wilmar M. Wiersinga ◽  
Ad M. Verbeek ◽  
Maarten Ph. Mourits ◽  
...  
Keyword(s):  
Disease Activity ◽  
Immunosuppressive Treatment ◽  
Graves Ophthalmopathy

A New Ultrasonographic Method to Detect Disease Activity and Predict Response to Immunosuppressive Treatment in Graves Ophthalmopathy

1994 ◽  
Vol 14 (2) ◽  
pp. 124
Author(s):  
Prummel MF ◽  
Suttorp-Schulten MSA ◽  
Wiers-inga WM ◽  
Verbeek AM ◽  
Mourits MP ◽  
...  
Keyword(s):  
Disease Activity ◽  
Immunosuppressive Treatment ◽  
Graves Ophthalmopathy

scholarly journals Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jiao Sun ◽  
Yameng Sui ◽  
Yunqing Wang ◽  
Lijun Song ◽  
Dong Li ◽  
...  
Keyword(s):  
T Cell ◽  
Disease Activity ◽  
Therapeutic Effect ◽  
Mean Fluorescence Intensity ◽  
Therapeutic Response ◽  
Severe Disease ◽  
T Cell Subsets ◽  
Poor Responders ◽  
Lower Plasma ◽  
Immunological Parameters

AbstractGalectin-9 (Gal-9) is a multifunctional immunomodulatory factor highly expressed in RA. This study aimed to investigate the expression of Gal-9 and its correlation with disease activity and therapeutic response in RA patients. Active RA patients were enrolled and treated with tacrolimus (TAC) alone or in combination therapy for 12 weeks in a prospective cohort study. Clinical and immunological parameters were recorded at baseline and week 12. We measured Gal-9 expression in different T cell subsets and in plasma. The disease activity of RA patients decreased after treatment. At baseline, the Gal-9 expression percentage was higher in the group with severe disease than in mild or moderate groups. After treatment, the Gal-9 expression in CD3+, CD4+, CD8+ and CD4-CD8− cell subsets decreased, as well as Gal-9 mean fluorescence intensity in CD3+, CD4+ and CD8+ T cells. Similarly, plasma Gal-9 levels were lower at week 12 than at baseline. Good responders showed significantly lower Gal-9 expression on CD3+ and CD4+ T cell subsets and lower plasma Gal-9 levels than poor responders. Gal-9 expression positively correlates with disease activity in RA patients. Gal-9 can be regarded as a new biomarker for evaluating RA activity and therapeutic effect, including TAC.

Longterm Outcomes and Damage Accrual in Patients with Childhood Systemic Lupus Erythematosus with Psychosis and Severe Cognitive Dysfunction

2013 ◽  
Vol 40 (4) ◽  
pp. 513-519 ◽  
Author(s):  
Lily Siok Hoon Lim ◽  
Arlette Lefebvre ◽  
Susanne Benseler ◽  
Earl D. Silverman
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Cognitive Dysfunction ◽  
Lupus Erythematosus ◽  
Clinical Course ◽  
Immunosuppressive Treatment ◽  
Damage Index ◽  
Response To Treatment ◽  
Systemic Lupus ◽  
Damage Accrual

Objective.(1) To describe the clinical course and response to treatment; and (2) to evaluate and compare damage accrual of distinct phenotypic subgroups of patients with clinically important psychiatric illness of pediatric systemic lupus erythematosus (pSLE).Methods.A single-center cohort study of patients with pSLE followed at a pediatric lupus clinic from 1985 to July 2009. Clinical course and response to treatment were studied. Remission was defined by absence of psychiatric/cognitive symptoms while receiving minimal doses of prednisone. Disease activity and damage were measured using SLE Disease Activity Index and SLE Damage Index.Results.Fifty-three children were included: 40 with psychosis and cognitive dysfunction (PSYC group) and 13 with isolated cognitive dysfunction (COG group). All received immunosuppressive treatment. Eighteen of 32 treated with azathioprine required a change to cyclophosphamide for poor response but none on cyclophosphamide required a change. The median times to remission were 72 weeks (PSYC) and 70 weeks (COG). Eight patients (7 PSYC, 1 COG) experienced flare following response/remission. New damage was noted in 50% of children at a median of 11 months: 57% of PSYC group, 31% of COG group. Persistent cognitive dysfunction was seen in 16% of PSYC patients and 15% of COG patients.Conclusion.Most patients responded to immunosuppressive treatment, although median time to remission was > 1 year. Roughly half the patients acquired a new damage item, most of which did not interfere with functional abilities. Fewer than 20% of patients developed neuropsychiatric damage. Both phenotypes of psychiatric pSLE responded equally well to current treatment.

Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients

Lupus ◽  
2019 ◽  
Vol 28 (5) ◽  
pp. 667-674 ◽  
Author(s):  
N Abdelrahman ◽  
M W Beresford ◽  
V Leone ◽  
Keyword(s):  
Disease Activity ◽  
Lupus Erythematosus ◽  
Clinical Remission ◽  
Immunosuppressive Treatment ◽  
Inactive Disease ◽  
Juvenile Onset ◽  
Time To Diagnosis ◽  
National Cohort ◽  
Onset Systemic Lupus Erythematosus

Background and objectives The multisystem involvement and variable course of juvenile-onset systemic lupus erythematosus (JSLE) make it difficult to assess disease activity over time. International consensus definitions of inactive disease and clinical remission have been proposed. The aim of this study was to determine the proportion of patients meeting these criteria in a large national cohort of JSLE patients and the association between achieving inactive disease and clinical remission with disease activity at presentation and time to diagnosis. Methods Patients diagnosed with JSLE aged ≤17 years with a minimum of 12 months follow-up participating in the UK JSLE Cohort Study were assessed against these criteria at baseline, 1 year and final clinic visit. Results A total of 218 patients with mean follow-up duration of 4.7 years were included and analyzed at baseline visit, of which 93 and 209 were available for analysis at the 1-year and the last follow-up visits, respectively. Eighty-five percent at 1 year and 62% at final follow-up still had active disease while only 6% and 9%, respectively, achieved inactive disease according to the proposed criteria. The majority of patients continued to require immunosuppressive treatment despite their prolonged follow-up with only two patients achieving clinical remission on medication and none off medication. A large number of patients did not meet the criteria for inactive disease due to isolated laboratory abnormalities such as reduced lymphocyte count. Isolated low lymphocyte count was the reason for not fulfilling the inactive disease criteria in 20/79 (25%) patients at 1 year and 14/130 (11%) patients at final follow-up visit. No statistically significant differences in relation to time to diagnosis and disease activity at presentation were found between patients achieving inactive disease compared to those who did not, at 1 year and final follow-up. Conclusion The majority of patients failed to achieve the proposed criteria for inactive disease and continued to require immunosuppressive treatment. This reflects the high burden of disease in JSLE despite immunosuppressive therapy. A significant proportion of patients had isolated laboratory abnormalities of potentially limited clinical significance, suggesting that some modifications of the proposed criteria may be required.

Immunosuppressive treatment of Graves' ophthalmopathy

1990 ◽  
Vol 1 (8) ◽  
pp. 377-381 ◽  
Author(s):  
Wilmar M. Wiersinga
Keyword(s):  
Immunosuppressive Treatment ◽  
Graves Ophthalmopathy

Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity

2020 ◽  
Vol 30 (4) ◽  
pp. 2138-2141 ◽  
Author(s):  
Cesare Gagliardo ◽  
Stefano Radellini ◽  
Raffaella Morreale Bubella ◽  
Giorgia Falanga ◽  
Pierina Richiusa ◽  
...  
Keyword(s):  
Disease Activity ◽  
Lacrimal Gland ◽  
Graves Ophthalmopathy
Sign in / Sign up

Export Citation Format

Share Document